Overview

Study of Topical ABI-1968 in Subjects With Precancerous Anal Lesions Resulting From Human Papillomavirus (HPV) Infection

Status:
Completed
Trial end date:
2019-02-04
Target enrollment:
Participant gender:
Summary
This study evaluates the use of ABI-1968, a topical cream, in the treatment of anal precancerous lesions in adults with and without human immunodeficiency virus (HIV) infection.
Phase:
Phase 1
Details
Lead Sponsor:
Antiva Biosciences